ABCC7 p.Lys684Leu
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 16442101
[PubMed]
Frelet A et al: "Insight in eukaryotic ABC transporter function by mutation analysis."
No.
Sentence
Comment
135
K684L (NBD1) and K1333L (NBD2) diminished nucleotide-binding abilities.
X
ABCC7 p.Lys684Leu 16442101:135:0
status: NEW
PMID: 16551273
[PubMed]
Buyse F et al: "Replacement of the positively charged Walker A lysine residue with a hydrophobic leucine residue and conformational alterations caused by this mutation in MRP1 impair ATP binding and hydrolysis."
No.
Sentence
Comment
47
Cell culture and cell lines expressing MRP1 Cell lines expressing wild-type, K684L- and K1333L-mutated MRP1s and CFTR (cystic fibrosis transmembrane conductance regulator) were established previously [16,24,25] (but see [25a]).
X
ABCC7 p.Lys684Leu 16551273:47:77
status: NEW120 Since the amounts of MRP1 proteins in the membrane vesicles containing wild-type, K684L- and K1333L-mutated MRP1 were different, they were adjusted to a similar amount of MRP1 with membrane vesicles containing CFTR (1.692 µg of wild-type MRP1 + 1.308 µg of CFTR; 3 µg of K684L; 1.05 µg of K1333L + 1.95 µg of CFTR; 3 µg of CFTR) to determine the ATP-dependent LTC4 transport activity.
X
ABCC7 p.Lys684Leu 16551273:120:286
status: NEW186 Cells expressing K684L- or K1333L-mutated MRP1s are not multidrug-resistant Considering that the transport activities of K684L, K1333L and CFTR (or parental BHK) are approx.
X
ABCC7 p.Lys684Leu 16551273:186:17
status: NEWX
ABCC7 p.Lys684Leu 16551273:186:121
status: NEW